Chapter | The Risks of Medical Innovation: Risk Perception and Assessment in Historical Context | 2006

BioRisk: interleukin-2 from laboratory to market in the United States and Germany

Keywords: Product Development; Risk and Uncertainty; Health Testing and Trials; Pharmaceutical Industry; Biotechnology Industry; United States; Germany;

Format: Print

Citation:

Daemmrich, Arthur A. "BioRisk: interleukin-2 from laboratory to market in the United States and Germany." In The Risks of Medical Innovation: Risk Perception and Assessment in Historical Context, edited by Thomas Schlich, and Ulrich Tröhler, 242–261. Routledge, 2006.

Leaders of the Romanian telecommunications agency must decide about a proposed international merger and how to structure bandwidth auctions critical to the telecoms market. The case is designed to teach about regulatory choices from the perspective of a regulatory agency, but it also describes the competitive standing of domestic and international telecoms providers in Romania and the challenges of operating as a "foreign" multinational, even in the European Union where protection of national champions is supposedly obsolete. Policy tradeoffs are developed among approving, delaying, or denying the proposed merger of domestic Romtelecom with Greek-based Cosmote. Likewise, tradeoffs are described for bandwidth auctions, notably among public transparency, maximizing revenue, preventing collusion, promoting efficient use of spectrum, broadening coverage, and fostering innovation in products and services.

General Information

Academic Programs

Alumni

Faculty & Research

Recruit

Resources

Faculty & Research

BioRisk: interleukin-2 from laboratory to market in the United States and Germany

About the Author

More from the Author

Contact

Related Links

Resources